KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Assets (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Current Assets readings, the most recent being $404.3 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 4.18% to $404.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $404.3 million, a 4.18% decrease, with the full-year FY2025 number at $404.3 million, down 4.18% from a year prior.
  • Current Assets hit $404.3 million in Q4 2025 for Biocryst Pharmaceuticals, up from $355.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $566.1 million in Q4 2021 to a low of $252.7 million in Q3 2021.
  • Median Current Assets over the past 5 years was $437.1 million (2024), compared with a mean of $431.0 million.
  • Biggest five-year swings in Current Assets: surged 118.13% in 2021 and later decreased 28.88% in 2024.
  • Biocryst Pharmaceuticals' Current Assets stood at $566.1 million in 2021, then decreased by 8.77% to $516.5 million in 2022, then decreased by 3.98% to $496.0 million in 2023, then decreased by 14.92% to $422.0 million in 2024, then decreased by 4.18% to $404.3 million in 2025.
  • The last three reported values for Current Assets were $404.3 million (Q4 2025), $355.7 million (Q3 2025), and $398.5 million (Q2 2025) per Business Quant data.